An Independent Prediction of the effects of MFAP2 on Stomach Adenocarcinomas.

Abstarct MFAP2, an extracellular matrix protein, is elevated in squamous carcinoma of skin and neck, hepatocellular carcinoma, and stomach adenocarcinoma. Its molecular characteristics and prognostic usefulness in stomach adenocarcinoma (STAD) have not been documented. A study using Prognoscan, Ualcan, Kaplan-Meier Plotter, Linkedomics, GEPIA2, TIMER, and a timer portal and Spearman's correlation phase coefficient found that MFAP2 expression was increased and validated in TCGA-STAD tumor tissues. Higher MFAP2 terms were related to lower survival in TCGA and cohort. MFAP2 expression was found to be an independent risk factor for average survival, disease-specific survival, and progression-free survival in STAD. MFAP2 affects RNA transportation, oocyte meiosis, spliceosome, and ribosome biogenesis. It is also associated with B cells, CD4+ T cells, and neutrophils infiltration. B lymphocytes and dendritic cells predicted STAD prognosis. Closing the MFAP2 connection to macrophage marker genes is the immune response's fundamental goal, laying the groundwork for future studies on MFAP2's immunomodulatory role in STAD. KEYWORDS: MFAP2, prognosis, stomach cancer.